Your session is about to expire
← Back to Search
PTCy + Sirolimus/VIC-1911 for Acute Leukemia Post-transplant Care
Study Summary
This trial is testing a new combination of drugs to prevent GVHD and relapse after alloHCT.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My heart, lungs, liver, and kidneys are functioning well, and I don't have active infections or certain viruses.I agree to use birth control during and for 60 days after my treatment ends.My leukemia is in complete remission, or I have a low blast count in myelodysplasia/myelofibrosis, or my lymphoma responds well to chemotherapy.I agree to use birth control during and for 60 days after treatment.I am 18 years old or older.I am mostly able to carry out my daily activities.I cannot undergo intense bone marrow radiation due to high risk.I can take medicine by mouth.I will start maintenance therapy before day 75 after my transplant.
- Group 1: PTCy/sirolimus plus VIC-1911
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is it a requirement that potential participants be over the age of 18?
"This trial is only for people aged 18 to 60. Out of the 2377 total clinical trials, 376 are for minors and 2001 are for senior citizens."
How many test subjects are required for this experiment?
"Yes, if you're interested in participating in this study you may be eligible as recruitment is still open. The trial was first posted on March 17th, 2022 and updated April 12th, 2022. Right now, the study is looking for 75 patients at a single site."
Is this research project still recruiting patients for participation?
"The most recent update on clinicaltrials.gov shows that this medical trial is still looking for patients. The study was first posted on March 17th, 2022 and was updated April 12th, 75 people are needed from a single location."
What are the inclusionary and exclusionary criteria for this particular research project?
"This trial seeks 75 individuals aged 18 to 60 who have myelodysplastic syndromes. In addition, patients must meet at least one of the following criteria: acute leukemia in complete remission, or myelodysplasia with <5% blasts, or myeloproliferative neoplasm/myelofibrosis with <5% marrow or circulating blasts, chemosensitive Hodgkin or non-Hodgkin lymphoma. Furthermore, all participants must have a left ventricular ejection fraction ≥ 45%, AST and ALT < 2 times upper limit of normal, no active/uncontrolled infection"
Share this study with friends
Copy Link
Messenger